Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 13, 2020
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
[ Tue, Oct 13th 2020
] - WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $355 on, Oct 13th, 2020
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $357 to $355 on, Oct 13th, 2020.
Matthew has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020
- Carter Gould of "Barclays" Downgraded from Buy to Hold and Decreased Target to $280 on, Monday, June 22nd, 2020
These are the ratings of the 2 analyists that currently disagree with Matthew
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $342 on, Wednesday, August 19th, 2020
- Brian Skorney of "Baird" Maintained at Sell with Decreased Target to $228 on, Friday, June 19th, 2020
